Final Crenessity
Pharmacy benefit prior authorization guidance for Crenessity (crinecerfont) as adjunctive treatment to glucocorticoid replacement in adults and pediatric patients ≥ 4 years with classic congenital adrenal hyperplasia (CAH). Defines initial and continuation criteria, required prescriber specialties, dosing form considerations, approval durations, and documentation rights.
Annual Review Date and Last Revised Date listed as 11/20/2025.
Coverage Summary
Scope: Pharmacy benefit prior authorization guidance for Crenessity (crinecerfont) as adjunctive treatment to glucocorticoid replacement in classic congenital adrenal hyperplasia (CAH) for adults and pediatric patients ≥ 4 years of age. Coverage stance: covered_with_criteria. Initial approvals are for 6 months; continuation/extended approvals are for 1 year.